When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play.
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago.
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 10, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of up to 305,000 shares of Iovance's common stock to Daniel Kirby, the Company's new Chief Commercial Officer.
Iovance Biotherapeutics (IOVA -0.96%), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the company has encountered some success, including a crucial regulatory approval coming down last year, that hasn't been enough to seduce investors.
If you're looking for an under-the-radar stock that could deliver enormous gains in a defined time frame, the biopharmaceutical industry has you covered. Hardly a week goes by without clinical trial results or a regulatory decision that produces dramatic market movements.
SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 224,550 shares of Iovance's common stock to forty-one new, non-executive employees.
Now this is a fine way for a stock to greet the new year. On the back of a glowing analyst recommendation, Iovance Biotherapeutics's (IOVA 5.27%) shares closed Thursday more than 5% higher in price.
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance's common stock to forty-eight new, non-executive employees.
Investors are fortunate to have access to a universe of stocks that they can buy or sell at any given time. Sometimes, however, limiting your options can be a powerful exercise.